Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
SIE-1
Laboratorios Tillomed Spain S.L.U
Hormone receptor-positive early breast cancer in post-menopausal women
1 trial -
SNDX-275
Syndax Pharmaceuticals
Breast Cancer
1 trial -
SPARC1210
Advanced Accelerator Applications
Breast Cancer
1 trial -
SPARC1613
Advanced Accelerator Applications
Recurrent or Metastatic Breast Cancer
1 trial -
SPECT/CT imaging of FPI-2505 in patients with solid tumours; a phase 0 molecular imaging basket trial (SCOPE-study).
Lacuna Pharma Pty Ltd
small cell lung cancer, non-smallcell lung cancer, colorectal cancer, breast cancer, Pancreatic cancer and gastric cancer
1 trial -
STRO-002
SUTRO BIOPHARMA, INC.
Ovarian Cancer
2 trials -
SZ011 CAR-NK
The First People's Hospital of Lianyungang
Advanced Triple Negative Breast Cancer
1 trial -
SerineοΌOralοΌ
The First People's Hospital of Lianyungang
Advanced Colorectal Cancer
1 trial -
Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
Study of Abemaciclib with Pembrolizumab in Patients with Stage IV Lung Cancer or Breast Cancer
Eli Lilly Co.
Lung Cancer or Breast Cancer
1 trial -
Study of EGF816 in combination with selected targeted agents in EGFR-mutant NSCLC.
Novartis Pharmaceuticals
Patients with EGFR-mutant Non Small Cell Lung Cancer
1 trial -
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)
Merck Sharp and Dohme
Advanced Pancreatic cancer, Unresectable Glioblastoma and Variants, PD-1-exposed Advanced/Met HNSCC, Advanced/Met HNSCC, Advanced/Met NSCLC, Advance/Met RCC, Advanced/Met Gastric or GEJ adenocarcinoma, Ovarian Cancer. TNBC, Advanced Mesothelioma, Advanced Solid tumors(coformulation)
1 trial -
Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated ROS1-Positive Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb Australia Pty Ltd
Non-small Cell Lung Cancer (NSCLC)
1 trial -
Study of U3-1402 in subjects with non-small cell lung cancer
Daiichi Sankyo
METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG CANCER
1 trial -
Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors.
Novartis Pharmaceuticals
Nasopharyngeal Carcinoma, Triple Negative Breast Cancer, Microsatellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer, Cutaneous Melanoma
1 trial -
Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Hepatic Impairment
Taiho Pharma Netherlands B.V.
Solid tumor, Acute myeloid lymphoma (AML), Myelodysplastic syndrome (MDS)
1 trial -
Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Renal Impairment
Taiho Pharma Netherlands B.V.
Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors
1 trial -
Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery
Celgene Europe Limited
Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resection
1 trial -
Study which tests 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) in early or locally advanced non-small cell lung cancer patients who underwent surgery and adjuvant chemotherapy
Samsung Bioepis NL B.V.
Non-small cell lung cancer
1 trial -
Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Amgen
Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
1 trial -
TAEST16001
Chongqing Precision Biotech Co., Ltd
Liver Cancer Stage IV
1 trial -
TAK-385
Takeda
Hormone Treatment-naΓ―ve Participants With Prostate Cancer
1 trial -
TAK-981
Takeda
Head and Neck Cancer
1 trial -
TGI-5
TG THERAPEUTICS, INC.
CRC (Colorectal Cancer)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources